ClinicalTrials.gg
Sign In
Drug

Cisplatin clinical trials

Also written CDDP, Platinol and cis-DDP.

Includes 3 studies of Cisplatin Liposomal.

studies test it
1,444
open now
179
in phase 3
277
first study started
1990
Related medicines add 7 studies

Counted the way a researcher would: Cisplatin with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Cisplatin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Cisplatin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Dec 1978 · PLATINOL-AQ · NDA 018057 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cisplatin
1,057
DDP
60
Platinol-AQ
48
CACP
38
CPDD
37

Brand

Platinol
109
LiPlaCis
1

Development codes

cis-DDP
5
NDC 16729-288
1
SUB07483MIG
1

Other names

CDDP
111
cis-diamminedichloroplatinum
9
Cis-diamminedichloroplatinum II
3

In one entry with another drug

Given together, or one or the other

gemcitabine and cisplatin
13
docetaxel and cisplatin
9
Gemcitabine, Cisplatin
8
Pemetrexed/Cisplatin
5
Docetaxel, Cisplatin
5
Gemcitabine plus cisplatin
4
docetaxel, cisplatin, fluorouracil
4
Paclitaxel, Cisplatin
4

Studies by the year they started

1,428 studies that test it; most in 2007 (77); 2 more planned to start later

Studies that test Cisplatin, by start year
YearStudies
19901
19913
19921
19935
199411
19957
199614
199730
199833
199947
200036
200142
200252
200376
200452
200557
200655
200777
200869
200972
201053
201153
201240
201346
201441
201553
201654
201747
201833
201934
202032
202135
202227
202335
202451
202526
202628

By phase

A phase 1/2 study counts in both.

Early Phase 1
12
Phase 1
294
Phase 2
931
Phase 3
277
Phase 4
17
No phase
43

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
187
Head and Neck Neoplasms
80
Uterine Cervical Neoplasms
75
Squamous Cell Carcinoma of Head and Neck
65
Stomach Neoplasms
65
Urinary Bladder Neoplasms
62
Esophageal Neoplasms
61
Nasopharyngeal Carcinoma
43
Breast Neoplasms
42
Pancreatic Neoplasms
33
Lung Neoplasms
32
Mesothelioma, Malignant
23

Who runs them

Industry 174 · Other 1,270

National Cancer Institute (NCI) (58) · Memorial Sloan Kettering Cancer Center (53) · Eli Lilly and Company (49) · Sun Yat-sen University (40) · M.D. Anderson Cancer Center (37) · Gynecologic Oncology Group (36) · Fudan University (30) · Dana-Farber Cancer Institute (23)

Often tested with

Tested in the same studies.

Gemcitabine (321) · Paclitaxel (222) · Docetaxel (189) · Fluorouracil (156) · Carboplatin (136) · Etoposide (129) · Pemetrexed (113) · Doxorubicin (80)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 78 phase 3 studies under way

Cisplatin is the comparator. A study of two new drugs counts under both.

  • 6Izalontamab brengitecan · Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd. · next primary completion Dec 2028
  • 5Pembrolizumab · Merck Sharp & Dohme LLC, Astellas Pharma Global Development, Inc. · next primary completion May 2027
  • 4Carboplatin · Beihua Kong, Hoffmann-La Roche · next primary completion Jun 2027
  • 4Durvalumab · AstraZeneca
  • 3Trastuzumab deruxtecan · AstraZeneca · next primary completion Jun 2028
  • 3Rilvegostomig · AstraZeneca · next primary completion Jun 2028
  • 3Tremelimumab · AstraZeneca
  • 3Enfortumab vedotin · Astellas Pharma Global Development, Inc., Merck Sharp & Dohme LLC · next primary completion Mar 2030
Reaching primary completion within a year · 67, 17 in phase 3

Studies that test Cisplatin, phase 3 first.

Studies

Open first, then newest update. How each study uses Cisplatin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 1,444

See all 1,444 studies that test Cisplatin →

Given beside what is tested · 1,301 — Cisplatin is usual care or a partner of the new treatment

Showing 20 of 1,301.

As the comparator · 234 — what is tested is compared with Cisplatin

Showing 20 of 234.

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting1

Results posted4

Stopped1

Newly registered7

Show 2 more

Codes

What other systems call Cisplatin · ClinicalTrials.gg INT007223

  • MeSH (NLM) D002945CisplatinConfirmed NLM, Wikidata
  • UNII (FDA) Q20Q21Q62JCISPLATINConfirmed FDA, NLM, Wikidata
  • RxNorm 2555Confirmed FDA, Wikidata
  • Wikidata Q412415cisplatinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C376CisplatinOne source FDA
  • DrugBank DB00515One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.